Safety and efficacy of ivabradine in the treatment of patients with acute myocardial infarction: a real-world propensity score matching study
European Heart Journal: Acute Cardiovascular Care · 2026
DOI: 10.1093/ehjacc/zuag084 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2026. Verfasst von Tianshu Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second H…. Hauptthemen laut MEDLINE: Cardiovascular Agents, Ivabradine, Myocardial Infarction. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Innovation 2030, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Tianjin Municipal Key Research Project in Priority Areas of Traditional Chinese Medicine.
Abstract (Originalsprache)
Aims
Ivabradine, a selective If channel inhibitor, reduces heart rate without impairing myocardial contractility. Evidence regarding its safety and efficacy in the acute phase of acute myocardial infarction (AMI) remains limited and conflicting. Methods and results We analysed data from 136 033 patients with AMI admitted to 82 hospitals in Tianjin, China, between 2010 and 2024. Primary outcomes were in-hospital mortality and 1-year cardiac mortality; secondary outcomes included 1-year all-cause mortality and other adverse events. Propensity score matching (PSM) was used to balance baseline characteristics between patients receiving ivabradine during hospitalization and controls. Logistic regression and Cox proportional hazards models were used to estimate outcome associations. Pre-specified subgroup analyses were conducted. Robustness was assessed using inverse probability of treatment weighting, overlap weighting, E-value analysis, complete-case analysis, treatment-pattern comparator analysis according to background beta-blocker use, and beta-blocker dose-intensity analysis. After PSM, in-hospital ivabradine use was associated with higher in-hospital mortality [aOR, 1.66 (95% CI, 1.19–2.32); P = 0.003], 1-year cardiac mortality [aHR, 1.22 (95% CI, 1.01–1.47); P = 0.043], and 1-year all-cause mortality [aHR, 1.19 (95% CI, 1.01–1.40); P = 0.040] in the fully adjusted model. No significant differences were observed in other secondary outcomes. Subgroup analyses suggested stronger associations among patients aged ≥65 years. Additional analyses showed that the mortality association was most pronounced among patients receiving ivabradine without concomitant beta-blocker. Sensitivity analyses yielded directionally consistent findings.
Conclusion
In this large real-world AMI cohort, in-hospital ivabradine use was associated with higher in-hospital and 1-year mortality, without clear evidence of benefit for other secondary outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi Dis…
- Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Tianshu Gu, Xian Shao, Jun-Yu Liu, Su-Tao Hu, Tong Liu, Kang-Yin Chen
Förderung
- National Science and Technology Innovation 2030
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Tianjin Municipal Key Research Project in Priority Areas of Traditional Chinese Medicine
- National Natural Science Foundation of China
- Science and Technology Project of Tianjin Municipal Health Committee
- Key Science and Technology Support Project of Tianjin Science and Technology Bureau
- Key Research Project of Tianjin Education Commission
- Tianjin Key Medical Discipline Construction
Zitieren
APA
Gu, T., Feng, W., Shao, X., Liu, J. Y., Zhang, Y. K., Hu, S. T., Dai, W. B., Liu, T., & Chen, K. Y. (2026). Safety and efficacy of ivabradine in the treatment of patients with acute myocardial infarction: a real-world propensity score matching study. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuag084
Vancouver
Gu T, Feng W, Shao X, Liu JY, Zhang YK, Hu ST, et al. Safety and efficacy of ivabradine in the treatment of patients with acute myocardial infarction: a real-world propensity score matching study. European Heart Journal: Acute Cardiovascular Care. 2026. doi:10.1093/ehjacc/zuag084
BibTeX
@article{Gu2026,
author = {Gu, Tianshu and Feng, Wanlin and Shao, Xian and Liu, Jun-Yu and Zhang, Yu-Kun and Hu, Su-Tao and Dai, Wen-Bo and Liu, Tong and Chen, Kang-Yin},
title = {Safety and efficacy of ivabradine in the treatment of patients with acute myocardial infarction: a real-world propensity score matching study},
journal = {European Heart Journal: Acute Cardiovascular Care},
year = {2026},
doi = {10.1093/ehjacc/zuag084}
}
EUVIMED